BioSpace News Archive

Hansa Biopharma AB has on May 12, 2021 held its Annual General Meeting. In order to mitigate the spread of Covid-19, the Annual General Meeting was conducted by advance voting only, without physical presence of shareholders, proxies and third parties.

- ImmunoPhage™ platform programs and the VISTA program continue to advance - - New safety and efficacy data from ongoing Phase 1/2 combination study of SNS-301 in squamous cell carcinoma of the head and neck accepted for presentation at ASCO 2021 - - Patient dosing underway in second cohort of Phase 1/2 combination study of SNS-301 in patients with no prior treatment with PD-1 blockade - - Ended quarter with a strong cash position of $169.4 million,

Inovalon (Nasdaq: INOV), a leading provider of cloud-based platforms empowering data-driven healthcare, today announced that Keith Dunleavy, M.D., chief executive officer and chairman of the board of Inovalon, and Jonathan R. Boldt, chief financial officer of Inovalon, will present at the 49 th Annual J.P. Morgan Technology, Media and Communications Conference, which will be held virtually.

Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, announced the publication of preclinical data in the peer-reviewed journal Nature Communications, for its lead artificial antigen-presenting cell program, RTX-321, for the potential treatment of human papillomavirus 16-positive cancers.

Connect Biopharma Holdings Limited, a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, announced that the first patient has been dosed in a Phase 2 trial evaluating CBP-201 in adults with moderate-to-severe persistent asthma.

Ovid Therapeutics Inc., a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, announced that management will participate in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021 at 9:10 a.m. ET.

BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of liver disease and neurological and neuro-degenerative disorders and certain cancers, announced that it will host a research and development day on Wednesday, May 19, 2021 from 12:00pm – 2:00pm Eastern Time.

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, announced it will host a Virtual Clinical Day for analysts and accredited institutional investors with live video webcast on Thursday, May 20, 2021 from 11:00 AM – 1:00 PM ET.

Clinical Research Organization in Cancer and Colorectal Cancer Canada are partnering to endeavour to improve access to colorectal cancer clinical trials in Quebec.

Vote FOR MIMEDX’s Experienced and Highly Qualified Directors and Governance Enhancement Proposals